Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients (AEB071)
A 12 Month Open-label, Randomized, Multicenter, Sequential Cohort-group, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Cyclosporine in Combination With Everolimus, Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, 1425
- Novartis Investigative Site
-
Buenos Aires, Argentina, 1107
- Argentina
-
-
-
-
-
Sydney, Australia, 2050
- Australia
-
Sydney, Australia, 5011
- Australia
-
-
-
-
-
Innsbruck, Austria, 6020
- Austria
-
Wein, Austria, 1090
- Austria
-
-
-
-
-
Gent, Belgium, 9000
- Belgium
-
-
-
-
-
Sao Paulo, Brazil, 04038-002
- Brazil
-
-
-
-
-
Bogota, Colombia
- Novartis Investigative Site
-
Cali, Colombia
- Novartis Investigative Site
-
-
-
-
-
Praha, Czech Republic, 14021
- Czech Republic
-
-
-
-
-
Lille Cedex, France, 59037
- France
-
Toulouse, France, 31055
- France
-
-
-
-
-
Berlin, Germany, 10117
- Novartis Investigative Site
-
Heidelberg, Germany, 69120
- Novartis Investigative Site
-
-
-
-
-
Milano, Italy, 20100
- Italy
-
Milano, Italy, 20122
- Italy
-
-
-
-
-
Rotterdam, Netherlands, 3000CA
- Netherlands
-
-
-
-
-
Oslo, Norway, 0027
- Norway
-
-
-
-
-
Singapore, Singapore, 119074
- Novartis Investigative Site
-
-
-
-
-
Banska Bystrica, Slovakia, 97517
- Novartis Investigative Site
-
Kosice, Slovakia, 04066
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spain, 08024
- Spain
-
Madrid, Spain, 28034
- Spain
-
-
-
-
-
Zurich, Switzerland, 8091
- Novartis Investigative Site
-
-
-
-
-
Taipie, Taiwan, 10002
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Male and female patients 18 years or older
- Recipients of first kidney transplant from a deceased or living not related donor
Exclusion criteria
- Need for medication prohibited in the study
- Patients with heart disease (own or family history)
- Patients or donor HIV, Hepatitis B (HBsAg) or Hepatitis C (HCV) positive
- Patients with high immunological risks
- Patients with a history of cancer
- Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Neoral
|
twice daily
|
|
Active Comparator: AEB071 high dose with Cetican reduced dose
|
oral, twice daily
twice daily
|
|
Active Comparator: AEB071 low dose with Cetican standard dose
|
oral, twice daily
twice daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Primary efficacy failure, defined as a composite efficacy endpoint of treated biopsy proven acute rejection,(BPAR) graft loss, death or loss to follow-up, 3 months after transplantation.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Primary efficacy failure endpoint,defined as a composite efficacy endpoint of treated(BPAR),graft loss, death or loss to follow-up of additional treatment regimen at Month 6; renal function at Month 3, Month 6 and Month 12 post transplant using GFR; PK
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CAEB071A2206
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.